Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
Titel:
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
Auteur:
Leonardi, Sergio Rao, Sunil V. Harrington, Robert A. Bhatt, Deepak L. Gibson, C. Michael Roe, Matthew T. Kochman, Janusz Huber, Kurt Zeymer, Uwe Madan, Mina Gretler, Daniel D. McClure, Matthew W. Paynter, Gayle E. Thompson, Vivian Welsh, Robert C.